Compare SSTK & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SSTK | PRME |
|---|---|---|
| Founded | 2003 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 570.9M | 526.0M |
| IPO Year | 2012 | 2022 |
| Metric | SSTK | PRME |
|---|---|---|
| Price | $2.20 | $3.57 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 13 |
| Target Price | N/A | ★ $7.39 |
| AVG Volume (30 Days) | 901.5K | ★ 5.6M |
| Earning Date | 11-05-2026 | 11-12-2026 |
| Dividend Yield | ★ 44.49% | N/A |
| EPS Growth | ★ 23.76 | 18.18 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | N/A | $150.97 |
| Revenue Next Year | N/A | $18.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $2.20 | $2.67 |
| 52 Week High | $21.68 | $5.91 |
| Indicator | SSTK | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 24.82 | 43.80 |
| Support Level | N/A | $2.89 |
| Resistance Level | $4.67 | $3.74 |
| Average True Range (ATR) | 0.33 | 0.45 |
| MACD | -0.08 | -0.12 |
| Stochastic Oscillator | 1.24 | 5.02 |
Shutterstock Inc is a U.S.-based company that is engaged in the provision of digital content. The content segment, whose offerings include licenses for Images, Footage, Music, 3 Dimensional, and Generative AI content. Data, Distribution, and Service offerings address customer demand for products and services that are beyond its Content licenses. The company generates the majority of its revenue from Content offerings. Geographically the company generates the majority of its revenue from the Domestic market, but also has its presence in Europe and Rest of the Countries.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.